摘要
2004年上半年,医药行业上市公司业绩整体出现了首次滑坡。在资本市场上,投资者迫切需要对医药行业上市公司有一个清楚的认识。因此,本文通过建立上市公司绩效综合评价的因子分析模型,对我国证券市场21家医药行业上市公司2004年上半年的经营绩效进行了综合评价,得出了这21家上市公司绩效的综合得分和排序,并进行了综合分析,以期在一定程度上能为投资者理性投资提供参考,为上市公司提高绩效提供数据借鉴。
In the first half of 2004, the overall performances of listed companies in medicine industry dropped for the first time. In the capital market, investors are eager to know clearly the management performance of the listed companies in the medicine industry. Thus by building a factor analysis model, the author carries on comprehensive evaluation on 21 listed companies＇ performances in the medicine industry of China＇s security market, which helps to set the comprehensive scores and order of these 21 listed companies. Then the author analyzes these scores and order so that to a certain extent they can offer some references for the investors to invest rationally and for the listed companies to improve their performances.
关键词
医药行业
上市公司
因子分析
绩效
medicine industry
listed company
factor analysis
performance
